However, despite the promising results in experimental models, the efficacy of TRAIL in inducing apoptosis is hampered in a wide variety of cancer types due to the presence of intrinsic resistance mechanisms [19], representing a major limitation in the use of TRAIL-based therapies in the clinic and a current challenge. This evidence concerns the gene TNFSF10 and cancer.